Integra LifeSciences (IART) FY 2025 Conference September 03, 2025 12:45 PM ET Speaker0Okay. Good afternoon, everyone. My name is Vik Chopra. I'm one of the Medical Device Analysts at Wells Fargo. Pleased to introduce management from Integra Life Sciences for this session.Joining us for the company are Mojde Paul, President and CEO and Leah Knight, EVP and CFO. Thank you both for being here.Speaker1Thanks for having us. SoSpeaker0Mojde, I'm going to start with some high level questions. You've been CEO since ...

PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at two upcoming investor healthcare conferences: Wells Fargo Healthcare Conference on September 3, 2025, at 12:45 p.m. ETMorgan Stanley Healthcare Conference on September 10, 2025, at 8:30 a.m. ET A live webcast of the presentations will be availabl ...

Integra LifeSciences (IART 6.31%), a medical technology company specializing in neurosurgery, reconstructive, and tissue technologies, released its results for Q2 2025 on July 31, 2025. The most important takeaway was that the company's revenue (GAAP) exceeded expectations, coming in at $415.6 million—well above the GAAP consensus estimate of $395.0 million. Adjusted EPS (non-GAAP) slightly surpassed forecasts as well, hitting $0.45 compared to the expected $0.44. Despite this sales outperformance, Integra ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q COMMISSION FILE NUMBER 000-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE ...

Core Insights - Integra LifeSciences reported revenue of $415.61 million for the quarter ended June 2025, reflecting a year-over-year decline of 0.6% and an EPS of $0.45 compared to $0.63 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $395.64 million by 5.05%, and the EPS also surpassed the consensus estimate of $0.43 by 4.65% [1] Revenue Performance - Organic Revenue Growth was -1.4%, better than the average estimate of -6.3% based on four analysts [4] - Codman Specialty Surgical revenue totaled $303.96 million, exceeding the average estimate of $294.18 million by four analysts, representing a year-over-year change of +0.7% [4] - Tissue Technologies revenue was $111.65 million, compared to the estimated $101.48 million, showing a year-over-year decline of -4.1% [4] - Wound Reconstruction and Care revenue within Tissue Technologies was $84.75 million, surpassing the average estimate of $80.24 million, with a year-over-year change of -3.4% [4] - Private Label revenue in Tissue Technologies was $26.9 million, exceeding the two-analyst average estimate of $25.3 million, reflecting a year-over-year decline of -6.3% [4] Stock Performance - Shares of Integra have returned -8.5% over the past month, contrasting with the Zacks S&P 500 composite's +2.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - Total revenues for Q2 2025 were $415.6 million, reflecting a decline of approximately 0.6% on a reported basis and 1.4% on an organic basis compared to the prior year [17][18] - Adjusted EPS for the quarter was 45 cents, representing a 29% decline compared to the previous year [18] - Gross margin for the quarter was 60.7%, down 450 basis points year over year, primarily due to higher operational costs associated with remediation efforts [19] - Operating cash flow for the quarter was $9 million, with free cash flow being negative $11.2 million due to continued capital investments [24] Business Line Data and Key Metrics Changes - Specialty Surgical Segment (CSS) reported revenues of $304 million, reflecting growth of 0.7% on a reported basis and a decline of 0.3% on an organic basis [20] - Tissue Technology revenues were $111.6 million, down approximately 4% on both a reported and organic basis compared to the prior year [23] - The ENT business experienced growth below expectations due to reimbursement-driven market pressure, despite double-digit growth in certain product lines [21][62] Market Data and Key Metrics Changes - International performance within CSS declined by low single digits, primarily due to ship holds, which offset strong underlying demand from international markets, including high single-digit growth in China [22] - The company noted a slowdown in private label demand due to competitive pressures, impacting overall market expectations [54] Company Strategy and Development Direction - The company is focused on transforming its quality management system and executing its compliance master plan, which is seen as critical for operational readiness and risk reduction [8][14] - Strategic investments and disciplined cost management are being emphasized to enhance supply chain reliability and drive long-term growth [14][15] - The company is optimistic about the proposed Medicare payment changes favoring evidence-backed, cost-effective wound reconstruction products, positioning it well for future growth [31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the leadership positions in neurosurgery and tissue technology, citing sustained demand in attractive markets [14] - The company anticipates a revenue range of $410 million to $420 million for Q3 2025, representing approximately 8% to 10% reported growth [13] - For the full year, the revenue guidance has been updated to a range of $1.655 billion to $1.68 billion, reflecting increased visibility into ship hold and remediation outlook [26][27] Other Important Information - A goodwill impairment charge of approximately $511 million was recorded during the quarter, primarily driven by macroeconomic uncertainties [18] - The company ended the quarter with total liquidity of $1.1 billion, including $254 million in cash and short-term investments [25] Q&A Session Summary Question: Thoughts on CMS' proposed 2026 reimbursement changes - Management indicated that the majority of the business is in the acute care setting, so immediate impacts are not expected, but long-term opportunities are seen as favorable for the wound reconstruction portfolio [35][36] Question: Q3 EPS guidance below street expectations - Management explained that the Q3 guidance is consistent with Q2 performance, with a revenue step-up expected in Q4 driven by seasonal lift and supply recovery [38][39] Question: Impact of ship holds and compliance programs - Management expressed confidence in the progress made and estimated a $100 million impact for the year, with no new material ship holds anticipated [44][45] Question: Ability to win back customers after supply issues - Management noted that once products come off ship holds, they typically see a return to market share, although reintroducing some products may require additional effort [50][51] Question: Revenue growth expectations and guidance adjustments - Management clarified that the updated guidance reflects a more refined view of the full-year impact from ship holds and market demand declines [54] Question: Gross margin softness and future expectations - Management attributed the decline in gross margins to manufacturing variances and operational inefficiencies, projecting a full-year gross margin decline of about 300 basis points [58][59] Question: Expectations for ENT business growth - Management expects mid-single-digit growth for the ENT business moving forward, supported by investments in new products and clinical evidence [63][64]

EARNINGS PRESENTATION Q2 2025 July 31, 2025 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this presentation. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like "will," "believe," "ma ...

Integra LifeSciences (IART) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +4.65%. A quarter ago, it was expected that this medical device maker would post earnings of $0.43 per share when it actually produced earnings of $0.41, delivering a surprise of -4.65%.Over the last four quar ...

News Release Integra LifeSciences Reports Second Quarter 2025 Financial Results The Company reported GAAP gross margin of 50.4%, compared to 54.0% in the second quarter of 2024. Adjusted gross margin was 60.7%, compared to 65.2% in the prior year. Adjusted EBITDA for the second quarter of 2025 was $71.2 million, or 17.1% of revenue, compared to $83.8 million, or 20.0% of revenue, in the prior year. The Company reported a GAAP net loss of $(484.1) million, or $(6.31) per diluted share, in the second quarter ...

PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2025. Second Quarter 2025 Highlights "I am proud of our team's performance and execution in the second quarter. Our strong revenue performance is a testament to our disciplined progress and the solid underlying demand trends for our portfolio of neurosurgery and tissue technology produ ...